Cynata Therapeutics 2024 Investor Presentation iPSC Stem Cell

Cynata Therapeutics is a clinical-stage biopharmaceutical company developing its proprietary Cymerus iPSC-based platform to manufacture mesenchymal stem cell therapeutics. The company has demonstrated compelling clinical data across multiple indications including acute graft versus host disease, diabetic foot ulcer, and osteoarthritis, with major trial readouts expected through 2026.